Exhibit 10.51


 


  


ALLIQUA, INC.


 


Securities
Purchase Agreement


 


NOVEMBER 18, 2013


 




    	 



    	 



    

 


TABLE OF CONTENTS


 


	 	 	PAGE
	 	 	 
	ARTICLE	1  DEFINITIONS	1
	 	 	 
	ARTICLE	2  PURCHASE
    AND SALE	3
	 	 	 
	2.1	Purchase and Sale of Stock and Warrants; Closing	3
	2.2	Adjustments in Share Numbers and Prices	4
	2.3	Reserve Shares	4
	2.4	Closing Deliveries	4
	 	 	 
	ARTICLE	3  REPRESENTATIONS
    AND WARRANTIES	4
	 	 	 
	3.1	Representations and Warranties of the Company	4
	3.2	Representations and Warranties of the Investors	11
	 	 	 
	ARTICLE	4  OTHER
    AGREEMENTS OF THE PARTIES	13
	 	 	 
	4.1	Filing of Reports	13
	4.2	Listing of Shares	13
	4.3	Use of Proceeds	14
	4.4	Lock-Up	14
	 	 	 
	ARTICLE	5  CONDITIONS	14
	 	 	 
	5.1	Conditions Precedent to the Obligations of the Investors	14
	5.2	Conditions Precedent to the Obligations of the Company	15
	 	 	 
	ARTICLE	6  GENERAL
    PROVISIONS	15
	 	 	 
	6.1	Termination	15
	6.2	Fees and Expenses	15
	6.3	Entire Agreement	15
	6.4	Notices	16
	6.5	Amendments; Waivers	16
	6.6	Construction	16
	6.7	Successors and Assigns	16
	6.8	No Third-Party Beneficiaries	16
	6.9	Governing Law; Venue; Waiver of Jury Trial	17
	6.10	Survival	17
	6.11	Execution	17
	6.12	Severability	17
	6.13	Replacement of Certificates	17
	6.14	Remedies	18


 





	Exhibit A:	Form of Warrants







 




    	i



    	 



    

 


SECURITIES PURCHASE AGREEMENT


 


THIS SECURITIES
PURCHASE AGREEMENT (this “Agreement”), dated as of November 18, 2013, by and among Alliqua, Inc., a Florida
corporation (the “Company”), and each of the investors identified on the signature pages hereto (each, an “Investor”
and together, the “Investors”).


 


The parties hereto
agree as follows:


 


ARTICLE 1

DEFINITIONS


 


In addition to the
terms defined elsewhere in this Agreement, the following terms have the meanings indicated:


 


“Affiliate”
means, with respect to a Person, any Person that controls, is controlled by or is under common control with such first Person.
For purposes of this definition only, “control” means (a) to possess, directly or indirectly, the power to
direct the management or policies of a Person, whether through ownership of voting securities, by contract relating to voting
rights or corporate governance or otherwise, or (b) to own, directly or indirectly, fifty percent (50%) or more of the outstanding
securities or other ownership interest of such Person.


 


“Agreement”
has the meaning set forth in the Preamble.


 


“Business
Day” means any day (other than a Saturday, Sunday or a legal holiday) on which banks are open for general business in
New York, New York.


 


“Celgene
Transaction Documents” means that certain (a) Stock Purchase Agreement, dated as of November 14, 2103, by and between
the Company and Celgene Corporation (the “Celgene SPA”), (b) License, Marketing and Development Agreement,
dated as of November 14, 2013, by and between the Company and Anthrogenesis Corporation d/b/a CCT, and (c) Supply Agreement, dated
as of November 14, 2013, by and between the Company and Anthrogenesis Corporation d/b/a CCT.


 


“Closing”
means the closing of the purchase and sale of the Common Shares and Warrants pursuant to Section 2.1.


 


“Closing
Date” means the date and time of the Closing and shall take place at 4:00 p.m. EST on November 18, 2013, or on such
other date and time as is mutually agreed to by the Company and the Majority-in-Interest.


 


“Company”
has the meaning set forth in the Preamble.


 


“Common Shares”
has the meaning set forth in Section 2.1(a).


 


“Common Stock”
has the meaning set forth in Section 2.1(a).


 


“Convertible
Securities” means any stock or securities (other than Options) convertible into or exercisable or exchangeable for Common
Stock.


 




    	1



    	 



    

 


“Disclosure
Materials” has the meaning set forth in Section 3.1(g).


 


“Exchange
Act” means the Securities Exchange Act of 1934, as amended.


 


“GAAP”
has the meaning set forth in Section 3.1(g). 


 


“Intellectual
Property Rights” has the meaning set forth in Section 3.1(q).


 


“Investor”
or “Investors” has the meaning set forth in the Preamble. 


 


“knowledge”
of the Company means with respect to any statement made to the knowledge of the Company, that the statement is based upon
the actual knowledge, after reasonable due inquiry, of any executive officer of the Company as of the date of this Agreement.


 


“Lien”
means any lien, charge, claim, security interest, encumbrance, right of first refusal or other restriction.


 


“Majority-in-Interest”
means Investors holding at least a majority of the Common Shares then outstanding.


 


“Material
Adverse Effect” means (a) a material adverse effect on the results of operations, assets, business or financial condition
of the Company and the Subsidiaries taken as a whole on a consolidated basis or (b) a material and adverse effect on the
legality, validity or enforceability of this Agreement, provided, that none of the following alone shall be deemed, in and of
itself, to constitute a Material Adverse Effect: (x) a change in the market price or trading volume of the Common Stock, (y) changes
in general economic conditions or changes affecting the industry in which the Company operates generally (as opposed to Company-specific
changes) so long as such changes do not have a disproportionate effect on the Company and the Subsidiaries taken as a whole, or
(z) effects resulting from or relating to the announcement or disclosure of the sale of the Common Shares or other transactions
contemplated by, or being taken in connection with, this Agreement or the Celgene Transaction Documents.


 


“Material
Permits” has the meaning set forth in Section 3.1(r).


 


“Options”
means any outstanding rights, warrants or options to subscribe for or purchase Common Stock or Convertible Securities.


 


“Per Share
Purchase Price” has the meaning set forth in Section 2.1(a).


 


“Person”
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
a government or any department or agency thereof and any other legal entity.


 


“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, a partial proceeding, such as a deposition),
whether commenced or threatened in writing.


 


“Purchase
Price” has the meaning set forth in Section 2.1(a).


 




    	2



    	 



    

 


“SEC”
means the United States Securities and Exchange Commission.


 


“SEC Reports”
has the meaning set forth in Section 3.1(g).


 


“Securities
Act” means the Securities Act of 1933, as amended.


 


“Short
Sales” means all “short sales” as defined in Rule 200 promulgated under Regulation SHO under the
Exchange Act and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, swaps, derivatives
and similar arrangements.


 


“Subsidiary”
means any entity in which the Company, directly or indirectly, owns capital stock or holds an equity or similar interest.


 


“Trading
Day” means a day on which the Common Stock is traded on a Trading Market; provided, that in the event that the Common
Stock is not listed or quoted on a Trading Market, then Trading Day shall mean a Business Day.


 


“Trading
Market” means whichever of the New York Stock Exchange, the NYSE MKT, the NASDAQ Global Select Market, the NASDAQ Global
Market, the NASDAQ Capital Market, the OTC Bulletin Board or any over the counter market operated by OTC Markets Group Inc. (or
any similar organization or agency succeeding to its functions of reporting prices) on which the Common Stock is listed or quoted
for trading on the date in question.


 


“Transaction”
has the meaning set forth in Section 3.2(h).


 


“Transaction
Documents” means this Agreement, the Warrants and the schedules and exhibits referred to herein.


 


“Transfer
Agent” means Action Stock Transfer Corp., or any successor transfer agent for the Company.


 


“Warrant
Shares” has the meaning set forth in Section 2.3.


 


“Warrants”
has the meaning set forth in Section 2.1(b).


 


ARTICLE 2

PURCHASE AND SALE


 


2.1        Purchase
and Sale of Stock and Warrants; Closing.


 


(a)          Upon
the following terms and conditions, on the Closing Date the Company shall issue and sell to each Investor, and each Investor shall,
severally and not jointly, purchase from the Company, that number of shares of the Company’s common stock, par value $0.001
per share (the “Common Stock”), as is set forth on each such Investor’s signature page hereto (collectively,
the “Common Shares”), at a price per share equal to $0.082 (the “Per Share Purchase Price,”
and such amounts in the aggregate, the “Purchase Price”).


 




    	3



    	 



    

 


(b)          The
Company further agrees to issue to each Investor on the Closing Date, in consideration for the Purchase Price, a Warrant in substantially
the form attached hereto as Exhibit A (each a “Warrant” and collectively, the “Warrants”),
to purchase that number of shares of Common Stock as is equal to fifty percent (50%) of the number of Common Shares purchased
by each such Investor hereunder. The Warrants shall have an initial term of five (5) years from their issuance date and shall
have an initial exercise price per share equal to $0.13.


 


(c)          The
Closing shall take place by the electronic exchange of executed Transaction Documents.


 


2.2        Adjustments
in Share Numbers and Prices. In the event of any stock split, subdivision, dividend or distribution payable in shares of Common
Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares
of Common Stock), combination or other similar recapitalization or event occurring after the date hereof, each reference in this
Agreement to the number of Common Shares and the Per Share Purchase Price shall be amended to appropriately account for such event.


 


2.3        Reserve
Shares. The Company has authorized and has reserved and covenants to continue to reserve, free of preemptive rights and other
similar contractual rights of shareholders, a number of shares of Common Stock equal to the number of shares of Common Stock issuable
upon the exercise of the Warrants (the “Warrant Shares”).


 


2.4        Closing
Deliveries.


 


(a)          At
the Closing, the Company shall deliver or cause to be delivered to each Investor (i) a copy of the Company’s irrevocable
instructions to the Transfer Agent instructing the Transfer Agent to promptly deliver one or more stock certificates, free and
clear of all restrictive and other legends (except for a customary legend to the effect that the Common Shares have not been registered
under the Securities Act), evidencing the Common Shares purchased by such Investor hereunder, registered in the name of such Investor
and (ii) a Warrant to purchase that number of Warrant Shares equal to fifty percent (50%) of the number of Common Shares purchased
by such Investor hereunder.


 


(b)          At
the Closing, each Investor shall deliver or cause to be delivered to the Company the Purchase Price for such Investor’s
Common Shares and Warrants in United States dollars by wire transfer to an account designated in writing to such Investor by the
Company for such purpose.


 


ARTICLE 3

REPRESENTATIONS AND WARRANTIES


 


3.1        Representations
and Warranties of the Company. The Company hereby represents and warrants to the Investors that, except as set forth in the
SEC Reports or in the Schedules delivered concurrently herewith:


 




    	4



    	 



    

 


(a)          Organization
and Qualification. The Company is an entity duly organized, validly existing and in good standing under the laws of the State
of Florida, with the requisite legal authority to own and use its properties and assets and to carry on its business as currently
conducted. Each Subsidiary is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction
of its incorporation or formation. Neither the Company nor any Subsidiary is in violation of any of the provisions of its respective
certificate or articles of incorporation, formation, bylaws or other organizational or charter documents. The Company and each
Subsidiary is duly qualified to do business and is in good standing as a foreign corporation or other entity in each jurisdiction
in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure
to be so qualified or in good standing, as the case may be, would not, individually or in the aggregate, reasonably be expected
to result in a Material Adverse Effect.


 


(b)          Subsidiaries.
The Company owns or controls, directly or indirectly, all of the capital stock or comparable equity interests of each Subsidiary
free and clear of any Lien, and all issued and outstanding shares of capital stock or comparable equity interest of each Subsidiary
are validly issued and are fully paid, non-assessable and free of preemptive and similar rights; and the Company has no Subsidiaries
other than the following corporations: (i) AquaMed Technologies, Inc., a Delaware corporation, (ii) Alliqua Biomedical, Inc. a
Delaware corporation, and (iii) Hepalife Biosystems, Inc. a Nevada corporation.


 


(c)          Authorization;
Enforcement. The Company has the requisite corporate authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents to which it is a party and otherwise to carry out its obligations
hereunder and thereunder including the issuance and sale of the Common Shares and Warrants. The execution and delivery by the
Company of this Agreement and each of the other Transaction Documents to which it is party and the consummation by it of the transactions
contemplated hereby and thereby have been duly authorized by all necessary corporate action on the part of the Company and no
further consent or action is required by the Company, its Board of Directors or its shareholders. Each of the Transaction Documents
to which to Company is party to has been duly executed by the Company and is the valid and binding obligation of the Company enforceable
against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights
generally, and (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies.


 




    	5



    	 



    

 


(d)          No
Conflicts. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents it
is party to and the consummation by the Company of the transactions contemplated hereby and thereby do not, and will not, (i) conflict
with or violate any provision of the Company’s articles of incorporation, bylaws or other organizational or charter documents,
(ii) in any material respect, conflict with, or constitute a default (or an event that with notice or lapse of time or both
would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation (with or without
notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company debt or otherwise)
or other understanding to which the Company is a party or by which any property or asset of the Company is bound, or affected,
or (iii) in any material respect, result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other
restriction of any court or governmental authority to which the Company is subject (including, assuming the accuracy of the representations
and warranties of the Investors set forth in Section 3.2 hereof, federal and state securities laws and regulations and the rules
and regulations of any self-regulatory organization to which the Company or its securities are subject, including all applicable
Trading Markets), or by which any property or asset of the Company is bound or affected, except in the case of clauses (ii) and
(iii) such as would not, individually or in the aggregate, have a Material Adverse Effect. Neither the Company nor any Subsidiary
is as of the date hereof, nor after giving effect to the transactions contemplated hereby to occur at the Closing, will be Insolvent
(as defined below). For purposes of this Section 3.1(d), “Insolvent” means, with respect to the Company or
any Subsidiary (i) the present fair saleable value of such Person’s assets is less than the amount required to pay such
Person’s debts and liabilities, (ii) such Person is unable to pay its debts and liabilities, subordinated, contingent or
otherwise, as such debts and liabilities become absolute and matured, (iii) such Person intends to incur or believes that it will
incur debts that would be beyond its ability to pay as such debts mature or (iv) such Person has unreasonably small capital with
which to conduct the business in which it is engaged, as such business is now conducted and is proposed to be conducted.


 


(e)          The
Common Shares and Warrant Shares. The Common Shares are duly authorized and, when issued and paid for in accordance with this
Agreement, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens (other than restrictions
on transfer set forth in this Agreement or imposed by applicable securities laws) and will not be subject to preemptive or similar
rights of shareholders. When the Warrant Shares are issued in accordance with the terms of the Warrants, such shares will be duly
authorized, validly issued, fully paid and nonassessable, free and clear of all Liens (other than restrictions on transfer set
forth in this Agreement or imposed by applicable securities laws) and will not be subject to preemptive or similar rights of shareholders.


 


(f)          Capitalization.
The aggregate number of shares and type of all authorized, issued and outstanding classes of capital stock, Options and other
securities of the Company (whether or not presently convertible into or exercisable or exchangeable for shares of capital stock
of the Company) as of the date hereof is set forth on Schedule 3.1(f). All outstanding shares of capital stock are duly authorized,
validly issued, fully paid and nonassessable and have been issued in compliance in all material respects with all applicable securities
laws. Except as set forth on Schedule 3.1(f), the Company does not have outstanding any Options, script rights to subscribe to,
calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable
or exchangeable for, nor has it entered into any agreement giving any Person any right to subscribe for or acquire, any shares
of Common Stock, or securities or rights convertible or exchangeable into shares of Common Stock. Except for customary adjustments
as a result of stock dividends, stock splits, combinations of shares, reorganizations, recapitalizations, reclassifications or
other similar events, there are no anti-dilution or price adjustment provisions contained in any security issued by the Company
(or in any agreement providing rights to security holders) and the issuance and sale of the Common Shares will not obligate the
Company to issue shares of Common Stock or other securities to any Person (other than the Investor) and will not result in a right
of any holder of securities to adjust the exercise, conversion, exchange or reset price under such securities.




    	6



    	 



    

 


(g)          SEC
Reports; Financial Statements. The Company (i) has filed all reports required to be filed by it under the Exchange Act, including
pursuant to Section 13(a) or 15(d) thereof, for the 12 months preceding the date hereof on a timely basis or has received
a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension, and
(ii) has filed all reports required to be filed by it under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof,
for the two years preceding the date hereof. Such reports required to be filed by the Company under the Exchange Act, including
pursuant to Section 13(a) or 15(d) thereof, together with the exhibits thereto and the documents incorporated by reference therein,
being collectively referred to herein as the “SEC Reports” and, together with this Agreement and the Schedules
to this Agreement, the “Disclosure Materials”. As of their respective dates (or, if amended or superseded by
a filing prior to the Closing Date, then on the date of such filing), the SEC Reports filed by the Company complied in all material
respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations of the SEC promulgated
thereunder, and none of the SEC Reports, when filed (or, if amended or superseded by a filing prior to the date hereof, then on
the date of such filing) by the Company, contained any untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects
with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time
of filing (or, if amended or superseded by a filing prior to the Closing Date, then on the date of such filing). Such financial
statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent
basis during the periods involved (“GAAP”), except as may be otherwise specified in such financial statements,
the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP or may be condensed
or summary statements, and fairly present in all material respects the consolidated financial position of the Company and the
Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject,
in the case of unaudited statements, to normal, year-end audit adjustments. All material agreements to which the Company or any
Subsidiary is a party or to which the property or assets of the Company or any Subsidiary are subject are included as part of
or identified in the SEC Reports, to the extent such agreements are required to be included or identified pursuant to the rules
and regulations of the SEC.


 


(h)          Material
Changes; Undisclosed Events, Liabilities or Developments; Solvency. Since the date of the latest audited financial statements
included within the SEC Reports, except as specifically disclosed in the SEC Reports or as set forth in Schedule 3.1(h),
(i) there has been no event, occurrence or development that, individually or in the aggregate, has had or would reasonably
be expected to result in a Material Adverse Effect, (ii) neither the Company nor any Subsidiary has incurred any material
liabilities other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with
past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP
or required to be disclosed in filings made with the SEC, (iii) the Company has not altered materially its method of accounting
or changed its auditors, (iv) the Company has not declared or made any dividend or distribution of cash or other property
to its shareholders, in their capacities as such, or purchased, redeemed or made any agreements to purchase or redeem any shares
of its capital stock (other than in connection with repurchases of unvested stock issued to employees of the Company), and (v) the
Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock-based
plans. Neither the Company nor any Subsidiary has taken any steps to seek protection pursuant to any bankruptcy law nor does the
Company have any knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy proceedings or any
actual knowledge of any fact which would reasonably lead a creditor to do so.


 




    	7



    	 



    

 


(i)          Absence
of Litigation. There is no action, suit, claim, or Proceeding, or, to the Company’s knowledge, inquiry or investigation,
before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of
the Company, threatened against or affecting the Company or any Subsidiary that would, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect.


 


(j)          Compliance.
Except as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, (i) 
neither the Company nor any Subsidiary is in default under or in violation of (and no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company
or any Subsidiary received written notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is
bound (whether or not such default or violation has been waived), (ii) neither the Company nor any Subsidiary is in violation
of any order of any court, arbitrator or governmental body, and (iii) neither the Company nor any Subsidiary is or has been
in violation of any statute, rule or regulation of any governmental authority. The Company has not taken, in violation of applicable
law, any action designed to or that would have reasonably expected to cause or result in stabilization or manipulation of the
price of the Common Stock to facilitate the sale of the Common Shares and Warrants.


 


(k)          Placement
Agent’s Fees. The Company shall be responsible for the payment of any placement agent’s fees, financial advisory
fees, or brokers’ commission (other than for persons engaged by the Investor or its Affiliates) relating to or arising out
of the issuance of the Common Shares and Warrants to the Investors pursuant to this Agreement. The Company shall pay, and hold
the Investors harmless against, any liability, loss or expense (including, without limitation, reasonable attorney’s fees
and out-of-pocket expenses) arising in connection with any such claim for fees arising out of the issuance of the Common Shares
and Warrants pursuant to this Agreement. Except for Summer Street Research Partners (“Summer Street”),
as placement agent in connection with the offer and sale of Common Shares and Warrants pursuant this Agreement, which the Company
has agreed to pay a cash fee of 7% of the Purchase Price and issue a warrant, in the form of the Warrant, to purchase such number
of shares of Common Stock equal to 7% of the number of Common Shares sold pursuant to this Agreement, the Company does not intend
to pay any placement agent’s fees, financial advisory fees, or brokers’ commissions in connection with the sale of
the Common Shares and Warrants.


 




    	8



    	 



    

 


(l)          Private
Placement; Investment Company; U.S. Real Property Holding Corporation. Neither the Company nor any of its Affiliates nor,
any Person acting on the Company’s behalf has, directly or indirectly, at any time within the past six months, made any
offer or sale of any security or solicitation of any offer to buy any security under circumstances that would (i) eliminate
the availability of the exemption from registration under Regulation D under the Securities Act in connection with the offer
and sale by the Company of the Common Shares and Warrants as contemplated hereby or (ii) cause the offering of the Common
Shares and Warrants pursuant hereto to be integrated with prior offerings by the Company for purposes of any applicable law, regulation
or shareholder approval provisions, including, without limitation, under the rules and regulations of any Trading Market. Assuming
the accuracy of the representations and warranties of the Investors set forth in Section 3.2, no registration under the Securities
Act is required for the offer and sale of the Common Shares and Warrants by the Company to the Investor as contemplated hereby.
The Company is not required to be registered as, and is not an Affiliate of, an “investment company” within the meaning
of the Investment Company Act of 1940, as amended. The Company is not required to be registered as a United States real property
holding corporation within the meaning of the Foreign Investment in Real Property Tax Act of 1980.


 


(m)         Registration
Rights. The Company has not granted or agreed to grant to any Person any rights (including “piggy-back” registration
rights) to have any securities of the Company registered with the SEC or any other governmental authority that have not expired
or been satisfied or waived.


 


(n)          Application
of Takeover Protections. The Company and its Board of Directors have taken all necessary action, if any, including under the
Florida Business Corporation Act, to render inapplicable any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or other similar anti-takeover provision under the Company’s charter documents
or the laws of its state of incorporation that is or could become applicable to the Investors or their Affiliates as a result
of the Investors and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including,
without limitation, as a result of the Company’s issuance of the Common Shares and Warrants to the Investors and the Investors’
ownership thereof.


 


(o)          Disclosure.
All written disclosure provided by the Company to the Investors regarding the Company, its business and the transactions contemplated
hereby are true and correct in all material respects and do not contain any untrue statement of a material fact or omit to state
any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were
made, not misleading. To the Company’s knowledge, no event or circumstance has occurred or information exists with respect
to the Company or any Subsidiary or their respective business, properties, operations or financial condition, which, under applicable
law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so publicly announced
or disclosed.


 




    	9



    	 



    

 


(p)          Transactions
With Affiliates and Employees. Except as set forth on Schedule 3.1(p), none of the officers, directors or employees of the
Company is presently a party to any transaction with the Company that would be required to be reported on Form 10-K by Item 13
thereof pursuant to Regulation S-K Item 404(a) (other than for ordinary course services as employees, officers or directors),
including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental
of real or personal property to or from, or otherwise requiring payments to or from any such officer, director or employee or,
to the Company’s knowledge, any corporation, partnership, trust or other entity in which any such officer, director, or
employee has a substantial interest or is an officer, director, trustee or partner.


 


(q)          Patents
and Trademarks. The Company and each Subsidiary owns, or possesses adequate rights or licenses to use, all trademarks, trade
names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals,
governmental authorizations, trade secrets and other intellectual property rights (“Intellectual Property Rights”)
necessary to conduct their respective businesses as now conducted. The Company does not have any knowledge of any infringement
by the Company or any Subsidiary of Intellectual Property Rights of others and there is no claim, action or proceeding being made
or brought, or to the knowledge of the Company, being threatened, against the Company or any Subsidiary regarding its Intellectual
Property Rights.


 


(r)          Regulatory
Permits. The Company and each Subsidiary possesses all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as presently conducted
and described in the SEC Reports (“Material Permits”), except where the failure to possess such permits would
not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, and neither the Company
nor any Subsidiary has received any written notice of proceedings relating to the revocation or modification of any Material Permit.


 


(s)          Employee
Relations. Neither the Company nor any Subsidiary is a party to any collective bargaining agreement or employs any member
of a union. The Company believes that its relations with its employees is as disclosed in the SEC Reports. During the period covered
by the SEC Reports, no executive officer or key employee of the Company or any Subsidiary has notified the Company or any Subsidiary
that such officer or key employee intends to leave the Company or a Subsidiary, as applicable, or otherwise terminate such officer’s
or key employee’s employment with the Company or a Subsidiary, as applicable. To the knowledge of the Company, no executive
officer or key employee of the Company or any Subsidiary is in violation of any material term of any employment contract, confidentiality,
disclosure or proprietary information agreement, non-competition agreement, or any other contract or agreement or any restrictive
covenant, and the continued employment of each such executive officer or key employee does not subject the Company or any Subsidiary
to any liability with respect to any of the foregoing matters.


 




    	10



    	 



    

 


(t)          Labor
Matters. The Company and each Subsidiary is in compliance in all material respects with all federal, state, local and foreign
laws and regulations respecting labor, employment and employment practices and benefits, terms and conditions of employment and
wages and hours, except where failure to be in compliance would not, either individually or in the aggregate, reasonably be expected
to result in a Material Adverse Effect.


 


(u)          Listing
and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the
Company has taken no action designed to terminate the registration of the Common Stock under the Exchange Act nor has the Company
received any notification that the SEC is contemplating terminating such registration. The Company is in compliance with applicable
OTCQB trading qualification requirements. There are no proceedings pending or, to the Company’s knowledge, threatened against
the Company relating to the Common Stock’s continued qualification for trading on the OTCQB market.


 


3.2        Representations
and Warranties of the Investors. Each Investor, severally and not jointly, hereby represents and warrants to the Company
as follows:


 


(a)          Organization;
Authority. Such Investor has full power and authority to enter into and to consummate the transactions contemplated by this
Agreement and otherwise to carry out its obligations hereunder. The purchase by such Investor of the Common Shares and Warrants
hereunder has been duly authorized by all necessary corporate action on the part of such Investor. This Agreement has been duly
executed and delivered by such Investor and constitutes the valid and binding obligation of such Investor, enforceable against
it in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, and
(ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies.


 


(b)          No
Public Sale or Distribution. Such Investor is acquiring the Common Shares and Warrants for its own account and not with a
view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered under
the Securities Act or under an exemption from such registration and in compliance with applicable federal and state securities
laws, and such Investor does not have a present arrangement to effect any distribution of the Common Shares or Warrants to or
through any person or entity; provided, however, that by making the representations herein, such Investor does not
agree to hold any of the Common Shares or Warrant Shares for any minimum or other specific term and reserves the right to dispose
of the Common Shares or Warrant Shares at any time in accordance with or pursuant to a registration statement or an exemption
under the Securities Act.


 


(c)          Investor
Status. At the time such Investor was offered the Common Shares and Warrants, it was, and at the date hereof it is an “accredited
investor” as defined in Rule 501(a) under the Securities Act and as indicated by such Investor’s response to the investor
questionnaire attached hereto as Schedule A. Such Investor is not a registered broker dealer registered under Section 15(a) of
the Exchange Act, or a member of the Financial Industry Regulatory Authority, Inc. or an entity engaged in the business of being
a broker dealer.


 




    	11



    	 



    

 


(d)          Experience
of Such Investor. Such Investor, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Common Shares and Warrants, and has so evaluated the merits and risks of such investment. Such Investor understands that
it must bear the economic risk of this investment in the Common Shares and Warrants indefinitely, and is able to bear such risk
and is able to afford a complete loss of such investment.


 


(e)          Access
to Information.  Such Investor acknowledges that it has reviewed the Disclosure Materials and has been afforded: (i) the
opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning
the terms and conditions of the offering of the Common Shares and Warrants and the merits and risks of investing in the Common
Shares and Warrants; (ii) access to information (other than material non-public information) about the Company and its financial
condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment;
and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable
effort or expense that is necessary to make an informed investment decision with respect to the investment. Neither such inquiries
nor any other investigation conducted by or on behalf of such Investor or its representatives or counsel shall modify, amend or
affect such Investor’s right to rely on the truth, accuracy and completeness of the Disclosure Materials and the Company’s
representations and warranties contained in the Transaction Documents.


 


(f)          No
Conflicts. The execution, delivery and performance by such Investor of this Agreement and the consummation by such Investor
of the transactions contemplated hereby will not (i) to the extent such Investor is not a natural person, result in
a violation of the organizational documents of such Investor or (ii) conflict with, or constitute a default (or an event
which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment,
acceleration or cancellation of, any agreement, indenture or instrument to which such Investor is a party, or (iii) result
in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable
to such Investor, except in the case of clauses (ii) and (iii) above, for such that are not material and do not otherwise affect
the ability of such Investor to consummate the transactions contemplated hereby.


 


(g)          Restricted
Securities. Such Investor understands that the Common Shares, Warrants and Warrant Shares (upon issuance) are characterized
as “restricted securities” under the U.S. federal securities laws inasmuch as they are being acquired from the Company
in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold
without registration under the Securities Act only in certain limited circumstances. Such Investor further understands that the
certificates evidencing the Common Shares, Warrants and Warrant Shares purchased by it will contain the following legend:


 




    	12



    	 



    

 


THESE SECURITIES
HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON
AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY
APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS.


 


(h)          Prohibited
Transactions. Such Investor has not, directly or indirectly, and no Person acting on behalf of or pursuant to any understanding
with such Investor has, engaged in any purchases or sales in the securities, including derivatives, of the Company (including,
without limitation, any Short Sales (a “Transaction”) involving any of the Company’s securities) since
the time that such Investor was first contacted by the Company or any other Person regarding an investment in the Company. Such
Investor covenants that neither it nor any Person acting on its behalf or pursuant to any understanding with such Investor will
engage, directly or indirectly, in any Transactions in the securities of the Company (including Short Sales) prior to the time
the transactions contemplated by this Agreement are publicly disclosed.


 


ARTICLE 4

OTHER AGREEMENTS OF THE PARTIES


 


4.1        Filing
of Reports. Until the date that all Investors (or any transferee that is an Affiliate of such Investor) cease to own any Common
Shares or Warrant Shares, the Company covenants to use its commercially reasonable efforts to (a) timely file (or obtain extensions
in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date
hereof pursuant to the Securities Act and the Exchange Act, (b) comply with the requirements of Rule 144(c) under the Securities
Act with respect to current public information about the Company, and (c) furnish to each Investor promptly upon request therefor
(i) a written statement by the Company as to its compliance with the requirements of Rule 144(c) under the Securities Act, and
the reporting requirements under the Securities Act and the Exchange Act, and (ii) such reports and documents of the Company as
such Investor may reasonably request to avail itself (or its Affiliates) of any similar rule or regulation of the SEC allowing
it (or its Affiliates) to sell any such securities without registration.


 


4.2        Listing
of Shares. Promptly following the date hereof, the Company shall take all necessary action to cause the Common Shares and
Warrant Shares to be qualified for trading on the OTCQB. If the Company applies to have its Common Stock or other securities traded
on any other principal stock exchange or market, it shall include in such application the Common Shares and Warrant Shares and
will take such other action as is necessary to cause such Common Shares and Warrant Shares to be so listed.


 




    	13



    	 



    

 


4.3        Use
of Proceeds. The Company will use the net proceeds from the sale of the Common Shares and Warrants for working capital and
general corporate purposes.


 


4.4        Lock-Up.
During the six (6) month period following the Closing, each Investor shall not, without the consent of the Company, issue,
sell, offer or agree to sell, grant any option for the sale of, pledge, enter into any swap, derivative transaction or other arrangement
that transfers to another, in whole or in part, any of the economic consequences of ownership of any of the Common Shares or Warrant
Shares (whether any such transaction is to be settled by delivery of Common Shares or Warrant Shares, other securities, cash or
other consideration) or otherwise dispose (or publicly announce the undersigned’s intention to do any of the foregoing)
of, directly or indirectly, any Common Shares or Warrant Shares. Notwithstanding anything in this Agreement to the contrary, subject
to the requirements of Section 6.7, no Investor shall be restricted from transferring any of the Common Shares or Warrant Shares
to any Affiliate of such Investor.


 


ARTICLE 5

CONDITIONS


 


5.1        Conditions
Precedent to the Obligations of the Investors.  The obligation of the Investors to purchase the Common Shares and Warrants
at the Closing is subject to the satisfaction or waiver by the Majority-in-Interest, at or before the Closing, of each of the
following conditions:


 


(a)          Representations
and Warranties. The representations and warranties of the Company contained herein shall be true and correct in all material
respects as of the date when made and as of the Closing as though made on and as of such date (except for representations and
warranties that speak as of a specific date, which shall be true and correct as of such specific date);


 


(b)          Performance.
The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the Closing;


 


(c)          No
Suspensions of Trading in Common Stock. Trading in the Common Stock shall not have been suspended by the SEC or any other
applicable authority at any time since the date of execution of this Agreement;


 


(d)          Absence
of Litigation. No action, suit or proceeding by or before any court or any governmental body or authority, against the Company
or pertaining to the transactions contemplated by this Agreement or their consummation, shall have been instituted on or before
the Closing Date, which action, suit or proceeding would, if determined adversely, have a Material Adverse Effect; and


 


(e)          No
Injunction. No preliminary or permanent injunction or other order issued by a court of competent jurisdiction which prevents
the consummation of the transactions contemplated by any of the Transaction Documents shall have been issued and remain in effect,
provided, however, that the parties shall use their respective commercially reasonable efforts to have any such order or injunction
lifted.


 




    	14



    	 



    

 


5.2        Conditions
Precedent to the Obligations of the Company. The obligation of the Company to sell the Common Shares and Warrants at the Closing
is subject to the satisfaction or waiver by the Company, at or before the Closing, of each of the following conditions:


 


(a)          Representations
and Warranties. The representations and warranties of each Investor contained herein shall be true and correct in all material
respects as of the date when made and as of the Closing Date as though made on and as of such date (except for representations
and warranties that speak as of a specific date, which shall be true and correct as of such specific date);


 


(b)          Performance.
Each Investor shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied with by such Investor at or prior to the Closing;
and


 


(c)          No
Injunction. No preliminary or permanent injunction or other order issued by a court of competent jurisdiction which prevents
the consummation of the transactions contemplated hereby shall have been issued and remain in effect, provided, however, that
the parties shall use their respective commercially reasonable efforts to have any such order or injunction lifted.


 


ARTICLE 6

GENERAL PROVISIONS


 


6.1        Termination.
This Agreement may be terminated by the Company or the Majority-in-Interest, by written notice to the other parties, if the
Closing has not been consummated by November 29, 2013; provided that no such termination will affect the right of any party
to sue for any breach by the other party (or parties) occurring prior to such termination.


 


6.2        Fees
and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent
fees, stamp taxes and other taxes and duties levied in connection with the sale and issuance of the Common Shares.


 


6.3        Entire
Agreement. This Agreement, together with the Exhibits and Schedules hereto, contains the entire understanding of the parties
with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral or written, with respect
to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules. At or after the Closing,
and without further consideration, the Company will execute and deliver to each Investor such further documents as may be reasonably
requested in order to give practical effect to the intention of the parties under this Agreement.


 




    	15



    	 



    

 


6.4        Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing
and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication
is delivered via facsimile or email at the facsimile number or email address specified in this Section  prior to 6:30 p.m.
(New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication
is delivered via facsimile or email at the facsimile number or email address specified in this Section on a day that is not a
Trading Day or later than 6:30 p.m. (New York City time) on any Trading Day, (c) the Trading Day following the date of deposit
with a nationally recognized overnight courier service, or (d) upon actual receipt by the party to whom such notice is required
to be given. The addresses, facsimile numbers and email addresses for such notices and communications are those set forth on the
signature pages hereof, or such other address or facsimile number as may be designated in writing hereafter, in the same manner,
by any such Person.


 


6.5        Amendments;
Waivers. No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an
amendment, by the Company and the Majority-in-Interest or, in the case of a waiver, by the party against whom enforcement of any
such waiver is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall
be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition
or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise
of any such right.


 


6.6        Construction.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit
or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties
to express their mutual intent, and no rules of strict construction will be applied against any party.


 


6.7        Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of
the Majority-in-Interest. Each Investor may assign its rights under this Agreement to any Person to whom such Investor assigns
or transfers any of such Investor’s Common Shares, provided (i) such Investor agrees in writing with the transferee
or assignee to assign such rights, and a copy of such agreement is furnished to the Company after such assignment, (ii) the Company
is furnished with written notice of the name and address of such transferee or assignee, (iii) following such transfer or assignment,
the further disposition of such securities by the transferee or assignee is restricted under the Securities Act and applicable
state securities laws, (iv) such transferee agrees in writing to be bound, with respect to the transferred Common Shares, by the
provisions hereof that apply to the “Investor” and such transferee is not a competitor of, or Affiliated with a competitor
of, the Company and (v) such transfer shall have been made in accordance with the applicable requirements of this Agreement and
with all laws applicable thereto.


 


6.8        No
Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.


 




    	16



    	 



    

 


6.9        Governing
Law; Venue; Waiver of Jury Trial. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS
AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. THE COMPANY AND THE INVESTORS
HEREBY IRREVOCABLY SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH
OF MANHATTAN FOR THE ADJUDICATION OF ANY DISPUTE BROUGHT BY THE COMPANY OR THE INVESTOR HEREUNDER, IN CONNECTION HEREWITH OR WITH
ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN, AND HEREBY IRREVOCABLY WAIVE, AND AGREE NOT TO ASSERT IN ANY SUIT, ACTION
OR PROCEEDING BROUGHT BY THE COMPANY OR ANY INVESTOR, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH
COURT, OR THAT SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND
CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED
MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT
AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN
SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. THE COMPANY AND THE INVESTORS HEREBY
WAIVE ALL RIGHTS TO A TRIAL BY JURY.


 


6.10      Survival.
The representations and warranties, agreements and covenants contained herein shall survive the Closing.


 


6.11      Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the
same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it
being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile
transmission or email attachment, such signature shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such facsimile or email-attached signature page were an
original thereof.


 


6.12      Severability.
If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability
of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will
attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall
incorporate such substitute provision in this Agreement.


 


6.13      Replacement
of Certificates. If any certificate or instrument evidencing any Common Shares is mutilated, lost, stolen or destroyed, the
Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution
therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss,
theft or destruction and the execution by the holder thereof of a customary lost certificate affidavit of that fact and an agreement
to indemnify and hold harmless the Company for any losses in connection therewith.


 




    	17



    	 



    

 


6.14      Remedies.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each
of the Investors and the Company will be entitled to seek specific performance under this Agreement. The parties agree that monetary
damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing
sentence and hereby agree to waive in any action for specific performance of any such obligation (other than in connection with
any action for a temporary restraining order) the defense that a remedy at law would be adequate.


 


[SIGNATURE PAGES TO FOLLOW]


 




    	18



    	 



    

 


IN WITNESS WHEREOF,
the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date
first indicated above.


 


	 	Alliqua, INC.
	 	 	 
	 	By:	/s/ Brian Posner
	 	 	Name:  Brian Posner
	 	 	Title: Chief Financial Officer
	 	 	 
	 	Address for Notice:
	 	 
	 	2150 Cabot Boulevard West
	 	Langhorne, PA  19047
	 	Attn: Chief Executive Officer
	 	Facsimile No.:  (215) 702-8535
	 	Telephone No.: _____________
	 	 
	 	With a copy (which shall not constitute notice) to:
	 	 
	 	Haynes and Boone, LLP
	 	30 Rockefeller Plaza
	 	26th Floor
	 	New York, New York 10112
	 	Attn: Rick Werner, Esq.
	 	Facsimile No.: (212) 884-8234
	 	Telephone No.: (212) 659-4974


  


Signature Page to Securities Purchase Agreement


 




    	 



    	 



    

 


	 	Investors:
	 	 
	 	[_____________________]
	 	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	Address for Notice:
	 	___________________________________
	 	___________________________________
	 	___________________________________
	 	Attention: ___________________________
	 	Facsimile: (___)______________________
	 	Telephone: (___)______________________


 


	 	Number of Common Shares:	_________________________
	 	 	 
	 	Number of Warrant Shares:	_________________________
	 	 	 
	 	Purchase Price:	$________________________
	 	 	 
	 	Tax ID Number:	_________________________


 


Delivery Instructions (if
different from above):





___________________________________


___________________________________


___________________________________


Attention: ___________________________


Facsimile: (___)______________________


Telephone: (___)______________________


 


Other Special Instructions:    ___________________________________________


 


Signature Page to Securities Purchase Agreement


 




    	 



    	 



    

 


Exhibit A


 





FORM OF WARRANT


 




    	 



    	 



    




 


Schedule A


 


ACCREDITED INVESTOR QUESTIONNAIRE


 


For Individual Investors
Only


 


(All individual investors
must INITIAL where appropriate. Where there are joint investors both parties must INITIAL):


 


Initial _______ I certify
that I have a “net worth” of at least $1 million either individually or through aggregating my individual holdings
and those in which I have a joint, community property or other similar shared ownership interest with my spouse. For purposes
of calculating net worth under this paragraph, (i) the primary residence shall not be included as an asset, (ii) to the extent
that the indebtedness that is secured by the primary residence is in excess of the fair market value of the primary residence,
the excess amount shall be included as a liability, and (iii) if the amount of outstanding indebtedness that is secured by the
primary residence exceeds the amount outstanding 60 days prior to investing in this Offering, other than as a result of the acquisition
of the primary residence, the amount of such excess shall be included as a liability.


 


Initial _______ I certify
that I have had an annual gross income for the past two years of at least $200,000 (or $300,000 jointly with my spouse) and expect
my income (or joint income, as appropriate) to reach the same level in the current year.


 


For Non-Individual
Investors 


 


(all Non-Individual
Investors must INITIAL where appropriate):


 


Initial _______ The
undersigned certifies that it is a partnership, corporation, limited liability company or business trust that is 100% owned by
persons who meet either of the criteria for Individual Investors, above.


 


Initial _______ The
undersigned certifies that it is a partnership, corporation, limited liability company or business trust that has total assets
of at least $5 million and was not formed for the purpose of investing in the Company.


 


Initial _______ The
undersigned certifies that it is an employee benefit plan whose investment decision is made by a plan fiduciary (as defined in
ERISA §3(21)) that is a bank, savings and loan association, insurance company or registered investment adviser.


 


Initial _______ The
undersigned certifies that it is an employee benefit plan whose total assets exceed $5,000,000 as of the date of the Purchase
Agreement.


 


Initial _______ The
undersigned certifies that it is a self-directed employee benefit plan whose investment decisions are made solely by persons who
meet either of the criteria for Individual Investors, above.


 




    	 



    	 



    

 


Initial _______ The
undersigned certifies that it is a U.S. bank, U.S. savings and loan association or other similar U.S. institution acting in its
individual or fiduciary capacity.


 


Initial _______ The
undersigned certifies that it is a broker-dealer registered pursuant to §15 of the Securities Exchange Act of 1934, as amended.


 


Initial _______ The
undersigned certifies that it is an organization described in §501(c)(3) of the Internal Revenue Code with total assets exceeding
$5,000,000 and not formed for the specific purpose of investing in the Company.


 


Initial _______ The
undersigned certifies that it is a trust with total assets of at least $5,000,000, not formed for the specific purpose of investing
in the Company, and whose purchase is directed by a person with such knowledge and experience in financial and business matters
that he is capable of evaluating the merits and risks of the prospective investment.


 


Initial _______ The
undersigned certifies that it is a plan established and maintained by a state or its political subdivisions, or any agency or
instrumentality thereof, for the benefit of its employees, and which has total assets in excess of $5,000,000.


 


Initial _______ The
undersigned certifies that it is an insurance company as defined in §2(a)(13) of the Securities Act of 1933, as amended,
or a registered investment company.